1yqy

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /><applet load="1yqy" size="450" color="white" frame="true" align="right" spinBox="true" caption="1yqy, resolution 2.3&Aring;" /> '''Structure of B. Anthr...)
Line 1: Line 1:
-
[[Image:1yqy.gif|left|200px]]<br /><applet load="1yqy" size="450" color="white" frame="true" align="right" spinBox="true"
+
[[Image:1yqy.gif|left|200px]]<br /><applet load="1yqy" size="350" color="white" frame="true" align="right" spinBox="true"
caption="1yqy, resolution 2.3&Aring;" />
caption="1yqy, resolution 2.3&Aring;" />
'''Structure of B. Anthrax Lethal factor in complex with a hydroxamate inhibitor'''<br />
'''Structure of B. Anthrax Lethal factor in complex with a hydroxamate inhibitor'''<br />
==Overview==
==Overview==
-
The primary virulence factor of Bacillus anthracis is a secreted, zinc-dependent metalloprotease toxin known as lethal factor (LF) that is, lethal to the host through disruption of signaling pathways, cell, destruction, and circulatory shock. Inhibition of this proteolytic-based, LF toxemia could be expected to provide therapeutic value in combination, with an antibiotic during and immediately after an active anthrax, infection. Herein is shown the crystal structure of an intimate complex, between a hydroxamate, (2R)-2-[(4-fluoro-3-methylphenyl)sulfonylamino]-N-hydroxy-2-(tetrahydro-2H, -pyran-4-yl)acetamide, and LF at the LF-active site. Most importantly, this molecular interaction between the hydroxamate and the LF active site, resulted in (i) inhibited LF protease activity in an enzyme assay and, protected macrophages against recombinant LF and protective antigen in a, cell-based assay, (ii) 100% protection in a lethal mouse toxemia model, against recombinant LF and protective antigen, (iii) approximately 50%, survival advantage to mice given a lethal challenge of B. anthracis Sterne, vegetative cells and to rabbits given a lethal challenge of B. anthracis, Ames spores and doubled the mean time to death in those that died in both, species, and (iv) 100% protection against B. anthracis spore challenge, when used in combination therapy with ciprofloxacin in a rabbit "point of, no return" model for which ciprofloxacin alone provided 50% protection., These results indicate that a small molecule, hydroxamate LF inhibitor, as, revealed herein, can ameliorate the toxemia characteristic of an active B., anthracis infection and could be a vital adjunct to our ability to combat, anthrax.
+
The primary virulence factor of Bacillus anthracis is a secreted zinc-dependent metalloprotease toxin known as lethal factor (LF) that is lethal to the host through disruption of signaling pathways, cell destruction, and circulatory shock. Inhibition of this proteolytic-based LF toxemia could be expected to provide therapeutic value in combination with an antibiotic during and immediately after an active anthrax infection. Herein is shown the crystal structure of an intimate complex between a hydroxamate, (2R)-2-[(4-fluoro-3-methylphenyl)sulfonylamino]-N-hydroxy-2-(tetrahydro-2H -pyran-4-yl)acetamide, and LF at the LF-active site. Most importantly, this molecular interaction between the hydroxamate and the LF active site resulted in (i) inhibited LF protease activity in an enzyme assay and protected macrophages against recombinant LF and protective antigen in a cell-based assay, (ii) 100% protection in a lethal mouse toxemia model against recombinant LF and protective antigen, (iii) approximately 50% survival advantage to mice given a lethal challenge of B. anthracis Sterne vegetative cells and to rabbits given a lethal challenge of B. anthracis Ames spores and doubled the mean time to death in those that died in both species, and (iv) 100% protection against B. anthracis spore challenge when used in combination therapy with ciprofloxacin in a rabbit "point of no return" model for which ciprofloxacin alone provided 50% protection. These results indicate that a small molecule, hydroxamate LF inhibitor, as revealed herein, can ameliorate the toxemia characteristic of an active B. anthracis infection and could be a vital adjunct to our ability to combat anthrax.
==About this Structure==
==About this Structure==
-
1YQY is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Bacillus_anthracis Bacillus anthracis] with ZN and 915 as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Anthrax_lethal_factor_endopeptidase Anthrax lethal factor endopeptidase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.83 3.4.24.83] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1YQY OCA].
+
1YQY is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Bacillus_anthracis Bacillus anthracis] with <scene name='pdbligand=ZN:'>ZN</scene> and <scene name='pdbligand=915:'>915</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Anthrax_lethal_factor_endopeptidase Anthrax lethal factor endopeptidase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.83 3.4.24.83] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1YQY OCA].
==Reference==
==Reference==
Line 17: Line 17:
[[Category: Felcetto, T.]]
[[Category: Felcetto, T.]]
[[Category: Guo, J.]]
[[Category: Guo, J.]]
-
[[Category: Michael, B.F.]]
+
[[Category: Michael, B F.]]
-
[[Category: Pivnichny, J.V.]]
+
[[Category: Pivnichny, J V.]]
-
[[Category: Shoop, W.L.]]
+
[[Category: Shoop, W L.]]
[[Category: Wiltsie, J.]]
[[Category: Wiltsie, J.]]
[[Category: Woods, A.]]
[[Category: Woods, A.]]
Line 30: Line 30:
[[Category: toxin]]
[[Category: toxin]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Wed Nov 21 06:59:45 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:08:09 2008''

Revision as of 14:08, 21 February 2008


1yqy, resolution 2.3Å

Drag the structure with the mouse to rotate

Structure of B. Anthrax Lethal factor in complex with a hydroxamate inhibitor

Overview

The primary virulence factor of Bacillus anthracis is a secreted zinc-dependent metalloprotease toxin known as lethal factor (LF) that is lethal to the host through disruption of signaling pathways, cell destruction, and circulatory shock. Inhibition of this proteolytic-based LF toxemia could be expected to provide therapeutic value in combination with an antibiotic during and immediately after an active anthrax infection. Herein is shown the crystal structure of an intimate complex between a hydroxamate, (2R)-2-[(4-fluoro-3-methylphenyl)sulfonylamino]-N-hydroxy-2-(tetrahydro-2H -pyran-4-yl)acetamide, and LF at the LF-active site. Most importantly, this molecular interaction between the hydroxamate and the LF active site resulted in (i) inhibited LF protease activity in an enzyme assay and protected macrophages against recombinant LF and protective antigen in a cell-based assay, (ii) 100% protection in a lethal mouse toxemia model against recombinant LF and protective antigen, (iii) approximately 50% survival advantage to mice given a lethal challenge of B. anthracis Sterne vegetative cells and to rabbits given a lethal challenge of B. anthracis Ames spores and doubled the mean time to death in those that died in both species, and (iv) 100% protection against B. anthracis spore challenge when used in combination therapy with ciprofloxacin in a rabbit "point of no return" model for which ciprofloxacin alone provided 50% protection. These results indicate that a small molecule, hydroxamate LF inhibitor, as revealed herein, can ameliorate the toxemia characteristic of an active B. anthracis infection and could be a vital adjunct to our ability to combat anthrax.

About this Structure

1YQY is a Single protein structure of sequence from Bacillus anthracis with and as ligands. Active as Anthrax lethal factor endopeptidase, with EC number 3.4.24.83 Full crystallographic information is available from OCA.

Reference

Anthrax lethal factor inhibition., Shoop WL, Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Felcetto T, Michael BF, Bansal A, Cummings RT, Cunningham BR, Friedlander AM, Douglas CM, Patel SB, Wisniewski D, Scapin G, Salowe SP, Zaller DM, Chapman KT, Scolnick EM, Schmatz DM, Bartizal K, MacCoss M, Hermes JD, Proc Natl Acad Sci U S A. 2005 May 31;102(22):7958-63. Epub 2005 May 23. PMID:15911756

Page seeded by OCA on Thu Feb 21 16:08:09 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools